Stromal cells move from the background into the center of Sjögren’s disease biology
Sjögren’s disease has long been framed as a disorder of lymphocytes and epithelial injury. That view is no longer complete. This review places non-epithelial stromal cells squarely inside the disease process, arguing that the connective tissue populations supporting salivary gland structure are not passive scaffolding but active participants in immune dysregulation, tissue maintenance, and pathological remodeling.
The clinical picture of Sjögren’s disease remains familiar: dry mouth, dry eyes, and, in some patients, extra-glandular involvement. The most severe manifestation is mucosa-associated lymphoid tissue, or MALT lymphoma. Those outcomes are usually discussed in terms of infiltrating immune cells or epithelial dysfunction, yet the stromal compartment shapes the local environment in which those abnormalities unfold. Fibroblasts, mesenchymal stem cells, and related stromal populations help organize the connective tissue matrix, and their disruption can alter gland development, normal secretory function, and injury responses.
This shift in emphasis matters because glandular inflammation is not only an immune-cell story. The tissue itself participates.
Single-cell sequencing is changing what salivary gland pathology can reveal
A major reason stromal biology has gained traction is the rise of single-cell sequencing technologies. Those methods make it possible to resolve cell populations that would otherwise be merged into a single “stromal” category. With that resolution, previously underappreciated cell types now appear to have distinct roles in salivary gland homeostasis and in the pathological response to autoimmune attack.
The review uses that technological shift as its conceptual anchor. Instead of treating stromal cells as structural bystanders, it organizes them as major components of the glandular ecosystem. In healthy tissue, they help maintain matrix integrity and support development. In Sjögren’s disease, they may be drawn into aberrant signaling loops that reinforce inflammation and tissue damage. The result is a more complex disease model in which the target organ is not merely injured by the immune system; it helps shape the immune response back.
Fibroblasts and mesenchymal stem cells may help drive the diseased microenvironment
The review centers on the major salivary gland stromal cell types, with particular attention to fibroblasts and mesenchymal stem cells. These cells are biologically well positioned to influence disease course because they sit at the interface between the extracellular matrix and immune activity. Fibroblasts can remodel the connective tissue scaffold, and mesenchymal stem cells contribute to tissue maintenance and repair. When those functions go awry, the glandular microenvironment can shift from one that preserves function to one that supports chronic pathology.
In Sjögren’s disease, that pathogenic shift may have several consequences. A dysfunctional stromal compartment can undermine normal gland architecture, alter the local response to inflammation, and create conditions that favor persistent lymphocyte recruitment. Once the tissue niche becomes permissive to chronic immune activity, epithelial dysfunction becomes harder to reverse. The clinical result is not just inflammation on histology; it is the slow collapse of salivary gland performance that patients experience as persistent dryness.
The tissue niche may also help explain lymphoma risk
The association between Sjögren’s disease and MALT lymphoma gives the stromal compartment added clinical weight. Lymphomagenesis in this setting is unlikely to arise from a single abnormal cell type. A tissue environment that sustains ongoing immune activation, chronic remodeling, and abnormal cellular crosstalk can support the conditions under which lymphoma develops. Stromal cells, by shaping that environment, may influence how and where malignant transformation takes hold.
This is one reason the review’s focus is more than academic. If stromal cells help organize the niche that permits persistent lymphoid infiltration, then they may also help explain why some patients progress to the most serious complications. Understanding the stromal contribution could improve how clinicians and researchers think about disease heterogeneity, risk stratification, and tissue-specific pathogenesis.
A mechanistic framework with clear research gaps
The review is explicit in its ambition: to detail the pathogenic mechanisms of salivary gland stromal cells and outline the key challenges ahead. Those challenges are substantial. Stromal cells are not a single uniform population, and their behavior may differ across glandular regions, disease stages, and microenvironmental cues. Single-cell methods have made the field visible, but visibility is not the same as mechanistic clarity.
Several questions remain embedded in the biology itself. Which stromal subsets are protective, and which are pathogenic? At what point does a repair-oriented cell become a driver of chronic inflammation? How do stromal cells interact with lymphocytes and epithelial cells to sustain autoimmune injury? Those questions are especially important in Sjögren’s disease because the disease is defined by both functional loss and structural remodeling. A complete explanation will need to account for both.
What gives this review its practical value is the way it reframes the gland as an interactive tissue system. Dry eye and dry mouth may begin as symptoms, but underneath them lies a coordinated failure of cellular relationships. The stromal compartment, once treated as background architecture, now appears to be part of the disease engine.
Why this perspective could matter for future therapy
The therapeutic implications are still conceptual, but they are difficult to ignore. If non-epithelial stromal cells actively sustain the diseased microenvironment, then targeting them could complement strategies aimed at lymphocytes or epithelial signaling. A treatment approach that ignores the tissue scaffold may leave one of the core drivers of persistent gland dysfunction untouched.
At the same time, the review does not claim that stromal biology has already yielded a clinical intervention. It instead positions the field at an earlier stage, where cellular classification, functional mapping, and microenvironmental analysis must come first. That is a realistic place for a review article to land. The strongest contribution here is not a finished therapeutic model but a cleaner explanation of why Sjögren’s disease can be so persistent, so structurally destructive, and so difficult to reverse once glandular injury is established.
The central message is direct: salivary gland stromal cells are no longer peripheral to Sjögren’s disease biology. They are part of the pathology, part of the maintenance of tissue homeostasis, and likely part of the explanation for the disease’s most serious outcomes.